Updated:
Holland Capital
Holland Capital is a Dutch mid-market private equity firm founded in 1981, investing in Benelux healthcare, technology, and food companies.
Holland Capital
Founded in 1981, Holland Capital is one of the longest-operating independent private equity firms in the Netherlands. Managing Partners Hubert Verbeek and Ewout Prins lead a team that invests out of a series of closed-end funds raised predominantly from Dutch institutional investors and family offices. The firm was originally established to provide equity capital to small and medium-sized Dutch enterprises at a time when the domestic private equity market was still nascent. Holland Capital pursues a buy-and-build strategy centered on majority and minority investments in Benelux-based companies with revenues typically between €10 million and €50 million. The firm concentrates on three core sectors: healthcare, technology, and sustainable food and agriculture. Portfolio companies have included ViroClinics, a virology contract research organization that contributed to COVID-19 vaccine development; Polyfluor Plastics, a specialist industrial components manufacturer; and Moba Group, a global leader in egg grading and packing equipment. Holland Capital structures investments as equity and subordinated debt, often partnering with management teams on succession-driven buyouts. Geographic focus remains firmly on the Netherlands and Flanders, with selective exposure to German and Nordic markets through portfolio-company expansion. Holland Capital operates from its Amsterdam office with a compact investment team that has remained stable across multiple fund cycles. The firm closed its most recent fund, Holland Capital VI, in 2022 at €100 million, exceeding its initial target (per the firm, 2022). In June 2023, the firm acquired a majority stake in Dutch healthcare staffing platform Zorgwerk, marking its tenth platform investment from the current fund. The firm's limited partners include major Dutch pension funds and insurers, reflecting a long track record of regulatory compliance under AFM supervision. Holland Capital does not operate adjacent philanthropic or real-asset vehicles. A defining structural feature of Holland Capital is its independence. The firm has not been acquired by a larger financial institution, nor has it evolved into a multi-asset manager—it remains a pure-play, lower-mid-market buyout house. This independence allows the firm to hold investments for extended periods without the pressure of a fixed fund-life constraint when both partners and management agree that value creation remains ahead. Succession planning for the next generation of partners is underway as the firm approaches its fifth decade, making governance and continuity a live issue for allocators evaluating commitment to its next fund vintage.
General information
Firm type
Private Equity
Year founded
1981
AUM
Undisclosed
Location
Region
Europe
Country
Netherlands
City
Amsterdam
Corporate office
Amsterdam, Netherlands
Principals
Hubert Verbeek
Managing Partner
Ewout Prins
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Holland Capital?
Investment decisions are made by the partnership led by Managing Partners Hubert Verbeek and Ewout Prins. The firm operates with a flat decision-making structure typical of independent Dutch private equity houses, with both partners actively involved in origination, due diligence, and portfolio management. Investment committee approval requires consensus among the senior partners.
What is Holland Capital's typical investment size and instrument?
Holland Capital typically invests €5 million to €25 million per transaction, using a combination of ordinary equity, preference shares, and shareholder loans. The firm targets majority and minority stakes in companies with revenues of €10 million to €50 million. Its most recent fund, Holland Capital VI, closed at €100 million in 2022 (per the firm, 2022), placing the firm in the lower mid-market segment by European standards.
How does Holland Capital source deals?
Deal sourcing relies heavily on Holland Capital's reputation and network within the Dutch accounting, legal, and corporate finance community accumulated since 1981. The firm focuses on proprietary and limited-auction processes, often acting as the first institutional investor in family-owned businesses seeking succession solutions. Sector specialization in healthcare and technology further supports its origination capability.
Does Holland Capital invest outside the Netherlands?
Holland Capital's core geographic mandate covers the Netherlands and the Flemish region of Belgium. The firm has selectively backed portfolio companies with expansion into Germany and the Nordic region, but it does not make platform investments outside the Benelux. This geographic concentration reflects a deliberate choice to maintain proximity-based governance.
What is Holland Capital's posture on co-investments?
Holland Capital occasionally syndicates transactions with other Dutch private equity firms and family offices on larger deals that exceed its fund concentration limits. The firm does not offer a formal co-investment program for limited partners but has co-invested alongside its own funds on an ad hoc basis with long-standing institutional backers. Co-investment terms follow the main fund's economics.
What sectors does Holland Capital explicitly avoid?
Holland Capital does not invest in real estate, financial services, or commodity-cyclical heavy industries. The firm's mandate explicitly excludes biotech drug discovery and other pre-revenue life-science models, preferring healthcare services and medical-technology companies with established reimbursement and revenue. Pure-play consumer discretionary businesses have also historically been absent from the portfolio.
How is Holland Capital regulated?
Holland Capital operates under the supervision of the Dutch Authority for the Financial Markets, the AFM, as a licensed manager of alternative investment funds under the AIFMD regime. The firm's fund structures are typically Dutch limited partnerships which have reported under the Dutch implementation of the AIFMD since 2014. Compliance and risk management functions sit in-house at the Amsterdam headquarters.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: